AstraZeneca’s new facility for the production of next generation biologics will create almost 900 new jobs.
Sweden Biomanufacturing Center (SBC) is located in Södertälje.
“It is no coincidence that we have chosen to launch this production site in Sweden. Sweden is in many ways attractive and we will continue to invest here, given Sweden’s strong position as a research nation, as a hub for innovation, development and production of new medicines that can change the lives for millions of people around the world,” says Leif Johansson, AstraZeneca’s Chairman.
During the last ten years, AstraZeneca Sweden has increased its investments in R&D in Sweden, and in total, during this period, the company has invested more than 150 billion SEK in R&D. Last year, AstraZeneca AB invested more than 17 billion SEK on R&D in Sweden.
Featured photo: Production, AstraZeneca, Södertälje